TY - JOUR AU - Raouf Ben Abdelali, AU - Vahid Asnafi, AU - Arnaud Petit, AU - Jean-Baptiste Micol, AU - Céline Callens, AU - Patrick Villarese, AU - Eric Delabesse, AU - Oumedaly Reman, AU - Stephane Lepretre, AU - Jean-Yves Cahn, AU - Gaelle Guillerm, AU - Céline Berthon, AU - Claude Gardin, AU - Bernadette Corront, AU - Thibaut Leguay, AU - Marie-Christine Béné, AU - Norbert Ifrah, AU - Guy Leverger, AU - Hervé Dombret, AU - Elizabeth Macintyre, PY - 2013/11/01 Y2 - 2024/03/28 TI - The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest JF - Haematologica JA - haematol VL - 98 IS - 11 SE - Articles DO - 10.3324/haematol.2013.086082 UR - https://haematologica.org/article/view/6833 SP - 1711-1717 AB - CALM-AF10 (also known as PICALM-MLLT10) is the commonest fusion protein in T-cell acute lymphoblastic leukemia, but its prognostic impact remains unclear. Molecular screening at diagnosis identified CALM-AF10 in 30/431 (7%) patients with T-cell acute lymphoblastic leukemia aged 16 years and over and in 15/234 (6%) of those aged up to 15 years. Adult CALM-AF10-positive patients were predominantly (72%) negative for surface (s)CD3/T-cell receptor, whereas children were predominantly (67%) positive for T-cell receptor. Among 22 adult CALM-AF10-positive patients treated according to the LALA94/GRAALL03-05 protocols, the poor prognosis for event-free survival (P=0.0017) and overall survival (P=0.0014) was restricted to the 15 T-cell receptor-negative cases. Among CALM-AF10-positive, T-cell receptor-negative patients, 82% had an early T-cell precursor phenotype, reported to be of poor prognosis in pediatric T-cell acute lymphoblastic leukemia. Early T-cell precursor acute lymphoblastic leukemia corresponded to 22% of adult LALA94/GRAALL03-05 T-cell acute lymphoblastic leukemias, but had no prognostic impact per se. CALM-AF10 fusion within early T-cell precursor acute lymphoblastic leukemia (21%) did, however, identify a group with a poor prognosis with regards to event-free survival (P=0.04). CALM-AF10 therefore identifies a poor prognostic group within sCD3/T-cell receptor negative adult T-cell acute lymphoblastic leukemias and is over-represented within early T-cell precursor acute lymphoblastic leukemias, in which it identifies patients in whom treatment is likely to fail. Its prognosis and overlap with early T-cell precursor acute lymphoblastic leukemia in pediatric T-cell acute lymphoblastic leukemia merits analysis. The clinical trial GRAALL was registered at Clinical Trials.gov number NCT00327678. ER -